Cancer Control in Central and Eastern Europe: Current Situation and Recommendations for Improvement
Jazyk angličtina Země Velká Británie, Anglie Médium print-electronic
Typ dokumentu časopisecké články, práce podpořená grantem
PubMed
27401890
PubMed Central
PMC5061531
DOI
10.1634/theoncologist.2016-0137
PII: theoncologist.2016-0137
Knihovny.cz E-zdroje
- Klíčová slova
- Cancer, Health care budget, Incidence, Mortality, Oncology, South-East Europe,
- MeSH
- časná detekce nádoru MeSH
- ekonomika farmaceutická MeSH
- incidence MeSH
- nádory epidemiologie etiologie mortalita prevence a kontrola MeSH
- registrace MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Geografické názvy
- Evropa MeSH
UNLABELLED: : The incidence of many cancers is higher in Western European (WE) countries, but mortality is frequently higher in Central and Eastern European (CEE) countries. A panel of oncology leaders from CEE countries participating in the South Eastern European Research Oncology Group (SEEROG) was formed in 2015, aiming to analyze the current status and trends of oncology care in CEE and to propose recommendations leading to improved care and outcomes. The SEEROG panel, meeting during the 11th Central European Oncology Congress, proposed the following: (a) national cancer control plans (NCCPs) required in all CEE countries, defining priorities in cancer care, including finance allocation considering limited health care budgets; (b) national cancer registries, describing in detail epidemiological trends; (c) efforts to strengthen comprehensive cancer centers; (d) that multidisciplinary care should be mandated by the NCCPs; (e) that smaller hospitals should be connected to multidisciplinary tumor boards via the Internet, providing access to specialized expertise; (f) nationwide primary prevention programs targeting smoking, obesity, and alcohol consumption and centrally evaluated secondary prevention programs for cervical, colorectal, and breast cancers; (g) prioritize education for all involved in cancer care, including oncology nurses, general practitioners, and palliative care providers; (h) establish outpatient care in day hospitals to reduce costs associated with the current inpatient model of care in CEE countries and to improve patients' quality of life; (i) long-term pharmacoeconomic evaluations of new therapies in CEE countries; (j) increase national oncology budgets in view of the higher mortality rates in CEE compared with WE countries; and (k) CEE countries urgently need help from the European Union to increase and monitor overall investment in cancer care. IMPLICATIONS FOR PRACTICE: Significant differences in cancer incidence and mortality have been observed between European countries. While the incidence of many cancer types is higher in Western European (WE) countries, the mortality is generally higher in Central and Eastern Europe (CEE). The primary purpose of this review was to describe the current status and trends of oncology care in the CEE region, to raise awareness among physicians, regulators, and payers, and to propose the most needed changes in order to make the oncology care in CEE closer to the WE standards.
Biometrika Healthcare Research Zagreb Croatia
Daily Chemotherapy Hospital Institute for Oncology and Radiology of Serbia Belgrade Serbia
Department of Breast Tumors Cancer Institute Prof Dr 1 Chiricuta Cluj Napoca Romania
Department of Medical Oncology Tumor Center Aarau Aarau Switzerland
Department of Oncology St László Teaching Hospital Budapest Hungary
Department of Oncology University Hospital Motol Charles University Prague Czech Republic
Division of Oncology and Hematology Department of Medicine 1 Medical University of Vienna Austria
Institute of Oncology Clinical Center University of Sarajevo Sarajevo Bosnia and Herzegovina
Institute of Radiotherapy and Oncology Skopje Macedonia
Medical University of Gdańsk Gdańsk Poland
National Hospital of Oncology Sofia Bulgaria
Oncology and Radiotherapy Clinic Clinical Centre of Montenegro Podgorica Montenegro
Oncology Institute University Hospital Center Mother Teresa Tirana Albania
Zobrazit více v PubMed
Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012. Eur J Cancer. 2013;49:1374–1403. PubMed
Ferlay J, Soerjomataram I, Ervik M et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available from: http://globocan.iarc.fr. Accessed June 19, 2015.
Znaor A, van den Hurk C, Primic-Zakelj M, et al. Cancer incidence and mortality patterns in South Eastern Europe in the last decade: Gaps persist compared with the rest of Europe. Eur J Cancer. 2013;49:1683–1691. PubMed
Karim-Kos HE, de Vries E, Soerjomataram I, et al. Recent trends of cancer in Europe: A combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s. Eur J Cancer. 2008;44:1345–1389. PubMed
Bosetti C, Bertuccio P, Malvezzi M, et al. Cancer mortality in Europe, 2005-2009, and an overview of trends since 1980. Ann Oncol. 2013;24:2657–2671. PubMed
La Vecchia C, Rota M, Malvezzi M, et al. Potential for improvement in cancer management: Reducing mortality in the European Union. The Oncologist. 2015;20:495–498. PubMed PMC
Chino F, Peppercorn J, Taylor DH, Jr, et al. Self-reported financial burden and satisfaction with care among patients with cancer. The Oncologist. 2014;19:414–420. PubMed PMC
Jemal A, Center MM, DeSantis C, et al. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev. 2010;19:1893–1907. PubMed
Colditz GA, Wolin KY, Gehlert S. Applying what we know to accelerate cancer prevention. Sci Transl Med. 2012;4:127rv4. PubMed PMC
Budapest Declaration. Available at http://www.seerog.eu/about/1-budapest-declaration. Accessed October 21, 2015.
De Angelis R, Sant M, Coleman MP, et al. Cancer survival in Europe 1999-2007 by country and age: Results of EUROCARE–5—A population-based study. Lancet Oncol. 2014;15:23–34. PubMed
Ades F, Senterre C, de Azambuja E, et al. Discrepancies in cancer incidence and mortality and its relationship to health expenditure in the 27 European Union member states. Ann Oncol. 2013;24:2897–2902. PubMed
World Health Organization. Global Health Observatory Data Repository. Available at http://apps.who.int/gho/data/node.main.510?lang=en. Accessed August 23, 2015.
The World Bank. World Bank Open Data. Available at http://data.worldbank.org/indicator. Accessed August 23, 2014.
Eurostat—Data Explorer. Available at http://appsso.eurostat.ec.europa.eu/nui/submitViewTableAction.do. Accessed August 30, 2015.
Goday A, Barneto I, García-Almeida JM, et al. Obesity as a risk factor in cancer: A national consensus of the Spanish Society for the Study of Obesity and the Spanish Society of Medical Oncology. Clin Transl Oncol. 2015;17:763–771. PubMed
Ligibel JA, Alfano CM, Courneya KS, et al. American Society of Clinical Oncology position statement on obesity and cancer. J Clin Oncol. 2014;32:3568–3574. PubMed PMC
Giacosa A, Barale R, Bavaresco L, et al. Cancer prevention in Europe: The Mediterranean diet as a protective choice. Eur J Cancer Prev. 2013;22:90–95. PubMed
Wolin KY, Carson K, Colditz GA. Obesity and cancer. The Oncologist. 2010;15:556–565. PubMed PMC
Impact CEOC study group Survey of CE Europe countries oncology opinion leaders. Results presented at: 11th Central European Oncology Congress; June 17–20, 2015; Opatija, Croatia.
Bray F, Jemal A, Torre LA, et al. Long-term realism and cost-effectiveness: Primary prevention in combatting cancer and associated inequalities worldwide. J Natl Cancer Inst. 2015;107:djv273. PubMed PMC
Bagnardi V, Rota M, Botteri E, et al. Alcohol consumption and site-specific cancer risk: A comprehensive dose-response meta-analysis. Br J Cancer. 2015;112:580–593. PubMed PMC
Grau C, Defourny N, Malicki J, et al. Radiotherapy equipment and departments in the European countries: Final results from the ESTRO-HERO survey. Radiother Oncol. 2014;112:155–164. PubMed
Purmonen T. Pharmacoeconomic Methods for Estimating Cost-Effectiveness and Budget Impact of Cancer Treatments in Finland [dissertation] Kuopio, Finland: University of Eastern Finland; 2012.
Asadzadeh Vostakolaei F, Karim-Kos HE, Janssen-Heijnen MLG, et al. The validity of the mortality to incidence ratio as a proxy for site-specific cancer survival. Eur J Public Health. 2011;21:573–577. PubMed
Chang S, Long SR, Kutikova L, et al. Estimating the cost of cancer: Results on the basis of claims data analyses for cancer patients diagnosed with seven types of cancer during 1999 to 2000. J Clin Oncol. 2004;22:3524–3530. PubMed
United Nations. Department of Economic and Social Affairs PD (2015). World Population Prospects: The 2015 Revision. Available at http://esa.un.org/unpd/wpp/DVD/. Accessed August 23, 2015.
The ESMO MOSES Task Force . Medical Oncology Status in Europe Survey (MOSES) Phase II. Lugano, Switzerland: European Society for Medical Oncology; 2006.
Vrdoljak E, Torday L, Sella A, et al. Insights into cancer surveillance in Central and Eastern Europe, Israel and Turkey. Eur J Cancer Care (Engl) 2015;24:99–110. PubMed
Coebergh JW, van den Hurk C, Louwman M, et al. EUROCOURSE recipe for cancer surveillance by visible population-based cancer RegisTrees in Europe: From roots to fruits. Eur J Cancer. 2015;51:1050–1063. PubMed
Bray F, Ren J-S, Masuyer E, et al. Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer. 2013;132:1133–1145. PubMed
Atun R, Ogawa TM-MJ. Analysis of National Cancer Control Programmes in Europe; 2009. Available at http://hdl.handle.net/10044/1/4204.
Lung cancer biomarker testing: perspective from Europe
Expenditures on Oncology Drugs and Cancer Mortality-to-Incidence Ratio in Central and Eastern Europe
